Kamat - Figure 26
Cancer in situ
FIG. 26: This study by Steinberg and colleagues[25] (Figure) showed that the patients with CIS who had <12 months' exposure to the last BCG and have had ≥2 courses of BCG therapy performed worst. This validates the BCG unresponsive category of patients and placed the timing a little closer to 12 months, hence validating allowing 9-12 months from prior exposure of BCG for CIS patients.
References
[25]
Steinberg RL, Thomas LJ, Mott SL, O'Donnell MA. Bacillus Calmette-Guérin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bladder Cancer. 2016;2:215−24 https://dx.doi.org/10.3233%2FBLC-150039
